Published in Biotech Business Week, November 27th, 2006
Revenues for the third quarter of 2006 include $8.3 million, $4.2 million related to Xopenex brand levalbuterol product sales and $4.1 million related to Lunesta brand eszopiclone sales, resulting from the reversal of reserves relating to rebates under the U.S. Department of Veterans Affairs (VA), Tricare Pharmacy Benefits...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.